On December 4, the Council of the European Union unanimously adopted conclusions on an enhanced patent system for the region. The package agreed, details of which were only released yesterday, covers major elements to bring about a single EU patent and establish a new patent court in the EU. Together, these will make it less costly for businesses to protect innovative technology and make litigation more accessible and predictable. The accord will pave the way for solving the outstanding issues to achieve a major reform of the EU patent system in the near future.
Industry group EFPIA's stance unchanged
Commenting on the issue to The Pharma Letter, a spokesman for the European Federation of Pharmaceutical Industries and Associations (EFPIA) said the research-based trade group's view of this is essentially unchanged to that stated in July when the European Commission's sector report came out, saying that the final version tones down earlier language and made constructive recommendations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze